Vertex Pharmaceuticals Incorporated announced its New Drug Submission for exagamglogene autotemcel has been accepted for Priority Review by Health Canada for the treatment of patients aged 12 years and older with sickle cell disease with recurrent vaso-occlusive crises and for the treatment of patients aged 12 years and older with transfusion-dependent beta thalassemia.The NDS will be part of an aligned review with Health Technology Assessment organizations, the Canadian Agency for Drugs and Technologies in Health and the Institut national d’excellence en sante et en services sociaux in Quebec. With Priority Review, the conventional review timeline of 300 days is reduced to 180 days.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Are Investors Vastly Underestimating CRISPR Therapeutics Stock (NASDAQ:CRSP)?
- Truist pharmaceuticals analyst holds an analyst/industry conference call
- Vertex Pharmaceuticals announces FDA clearance of VX-407 IND
- William Blair biotech analysts to hold an analyst/industry conference call
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
